Annual results and Q4 2020
Annual results and Q4 2020
Tuesday, January 26, 2021
Media release
Condensed financial report (PDF 0.9 MB)
Read the presentation transcript
Download the podcast (MP3 45 MB)
Download the presentation (PDF 3.6 MB)
Access our interactive slide deck (PDF 12 MB)
| Key figures2 | Continuing operations1 | ||
| Q4 2020 (USD m) |
Q4 2019 (USD m) |
% change (USD/cc) |
|
|---|---|---|---|
| Net sales | 12,770 | 12,403 | 3 (cc: 1) |
| Operating income | 2,644 | 1,823 | 45 (cc: 51) |
| Net income | 2,099 | 1,129 | 86 (cc: 93) |
| EPS (USD) | 0.92 | 0.50 | 84 (cc: 93) |
| Free cash flow | 3,342 | 3,488 | -4 |
Core |
|||
| Operating income | 3,501 | 3,462 | 1 (cc: 2) |
| Net income | 3,034 | 2,985 | 2 (cc: 3) |
| EPS (USD) | 1.34 | 1.32 | 2 (cc: 3) |
- Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.